The composition, now protected by patent number US10183047B2, was developed for its synergistic effect in improving the body’s lipid profile and endothelial function, according to the company.
“We are glad that USPTO has granted a well-deserved patent for cardiovascular health benefits of Crominex 3+, the most efficacious of several chromium supplements from the market,” said Dr Sanni Raju, CEO of Natreon.
“Crominex 3+ has amazing synergistic activity that showed significant improvement in endothelial function, lipid profile, hsCRP, as well as HbA1c, which are all important factors for cardiovascular health. Synergistic activity of Crominex 3+ is achieved by using totally natural materials.”
There is currently one published study listed on PubMed, the clinical trials database managed by the US National Library of Medicine at the National Institutes of Health, that supports Crominex 3+’s endothelial function and lipid profile benefits.
The study, conducted by Italian researchers, found that Crominex 3+ was among the functional foods associated with a significant improvement of endothelial function with enhanced cholesterol lowering effects. It was published in the journal BioMed Research International in January this year.
In a press release announcing the granted US patent, Natreon said that two clinical studies to be published soon show combining 10-20 mg of Crominex 3+ (200 mcg to 400 mcg of trivalent chromium) with 2 g of fish oil (600 mg of EPA + 400 mg of DHA) may enhance the health benefits of fish oil significantly.
“It is interesting to note that 10-20 mg of Crominex 3+ neither increases the size of the fish oil dosage form nor impacts the cost significantly, while enhancing fish oil’s numerous cardiovascular health benefits,” said Dr Raju.
